Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs
Outcomes of maternal/paternal tofacitinib exposure were similar to those expected in the general population; tofacitinib should not be used during pregnancy unless clearly necessary.
Authors
- Marla C. Dubinsky (ORCID: https://orcid.org/0000-0003-4968-5795)
- Xiang Guo
- María Chaparro (ORCID: https://orcid.org/0000-0002-9275-4242)
- Michelle Segovia
- Arthur Kavanaugh
- Nicole Kulisek
- Uma Mahadevan (ORCID: https://orcid.org/0000-0002-3067-8061)
- Ivana Vranić (ORCID: https://orcid.org/0000-0002-2990-4914)
- Joseph Wu (ORCID: https://orcid.org/0009-0006-3464-2556)
- Annette Diehl
Institutions
- University of San Diego (US)
- University of California, San Francisco (US)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- University of California San Diego (US)
- Hospital Universitario de La Princesa (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Universidad Autónoma de Madrid (ES)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.14309/ajg.0000000000003774
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00